Accueil>>Signaling Pathways>> Others>> Estrogen Receptor/ERR>>GDC-0927 Racemate (SRN-927 Racemate)

GDC-0927 Racemate (SRN-927 Racemate) (Synonyms: SRN-927 Racemate)

Catalog No.GC33193

GDC-0927 Racemate (SRN-927 Racemate) (SRN-927 Racemate) est un dégradeur du récepteur des œstrogènes, inhibe puissamment ER-α ; activité, avec un IC50 de 0,2 nM, et est utilisé dans la recherche de maladies liées au RE.

Products are for research use only. Not for human use. We do not sell to patients.

GDC-0927 Racemate (SRN-927 Racemate) Chemical Structure

Cas No.: 1443983-36-5

Taille Prix Stock Qté
5mg
552,00 $US
En stock
10mg
827,00 $US
En stock
25mg
1 792,00 $US
En stock
50mg
2 850,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GDC-0927 Racemate (SRN-927 Racemate) is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases.

GDC-0927 Racemate (Example 1) is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases. GDC-0927 Racemate reduces the viability of MCF7 cells with an IC50 of 0.21 nM[1].

[1]. Mehmet Kahraman, et al. Estrogen receptor modulator and uses thereof. WO2014205138A1.

Avis

Review for GDC-0927 Racemate (SRN-927 Racemate)

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GDC-0927 Racemate (SRN-927 Racemate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.